J PHARM SCI 2017
Special issue dedicated to Yuichi Sugiyama
Introduction
J Pharm Sci. 2017;106:2187. Editorial. Borchardt RT. PubMed
J Pharm Sci. 2017;106:2188-2194. Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist. Kusuhara H, Obach RS, Rostami-Hodjegan A, Pang KS, Hammarlund-Udenaes M, Derendorf H, Artursson P, Huang SM, Suzuki H, Terasaki T. PubMed
Clinical trials and translational medicine commentaries
J Pharm Sci. 2017;106:2204-2208. Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction. Galetin A, Zhao P, Huang SM. PubMed
J Pharm Sci. 2017 Sep;106:2209-2213. In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods. Yoshida K, Zhao P, Zhang L, Abernethy DR, Rekić D, Reynolds KS, Galetin A, Huang SM. PubMed
J Pharm Sci. 2017;106:2214-2218. Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access. Rekić D, Reynolds KS, Zhao P, Zhang L, Yoshida K, Sachar M, Piquette Miller M, Huang SM, Zineh I. PubMed
J Pharm Sci. 2017;106:2227-2230. Is Ethnic Variability in the Exposure to Rosuvastatin Explained Only by Genetic Polymorphisms in OATP1B1 and BCRP or Should the Contribution of Intrinsic Ethnic Differences in OATP1B1 Be Considered? Sugiyama Y, Maeda K, Toshimoto K. PubMed
J Pharm Sci. 2017;106:2231-2233. Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics. Benet LZ, Wu HF. PubMed
Mini reviews
J Pharm Sci. 2017;106:2245-2250. Transporters Involved in Metformin Pharmacokinetics and Treatment Response. Liang X, Giacomini KM. PubMed
J Pharm Sci. 2017;106:2251-2256. Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps. Okudaira N. PubMed
J Pharm Sci. 2017;106:2257-2264. A Critical View on In Vitro Analysis of P-glycoprotein (P-gp) Transport Kinetics. Saaby L, Brodin B. PubMed
Reviews
J Pharm Sci. 2017;106:2282-2294. Effect of Liver Disease on Hepatic Transporter Expression and Function. Thakkar N, Slizgi JR, Brouwer KLR. PubMed
J Pharm Sci. 2017;106:2295-2301. Model Systems for Studying the Role of Canalicular Efflux Transporters in Drug-Induced Cholestatic Liver Disease. Stieger B, Mahdi ZM. PubMed
J Pharm Sci. 2017;106:2302-2311. Recent Progress in Hepatocyte Culture Models and Their Application to the Assessment of Drug Metabolism, Transport, and Toxicity in Drug Discovery: The Value of Tissue Engineering for the Successful Development of a Microphysiological System. Tetsuka K, Ohbuchi M, Tabata K. PubMed
J Pharm Sci. 2017;106:2312-2325. Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings. Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. PubMed
J Pharm Sci. 2017;106:2335-2344. Imaging Probes and Modalities for the Study of Solute Carrier O (SLCO)-Transport Function In Vivo. Marie S, Cisternino S, Buvat I, Declèves X, Tournier N. PubMed
J Pharm Sci. 2017;106:2357-2367. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions. Chu X, Chan GH, Evers R. PubMed
J Pharm Sci. 2017;106:2368-2379. Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. Klein ME, Parvez MM, Shin JG. PubMed
J Pharm Sci. 2017;106:2380-2391. Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine. Marsousi N, Desmeules JA, Rudaz S, Daali Y. PubMed
Rapid communications
J Pharm Sci. 2017;106:2401-2406. Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors? Guo C, Yang K, Liao M, Xia CQ, Brouwer KR, Brouwer KLR. PubMed
Research articles
1. Drug discovery-development interface
J Pharm Sci. 2017;106:2412-2419. Identification of Bile Acids Responsible for Inhibiting the Bile Salt Export Pump, Leading to Bile Acid Accumulation and Cell Toxicity in Rat Hepatocytes. Oizumi K, Sekine S, Fukagai M, Susukida T, Ito K. PubMed
2. Pharmacokinetics, pharmacodynamics, drug transport, and metabolism
J Pharm Sci. 2017;106:2483-2490. Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1. Kamo S, Nakanishi T, Aotani R, Nakamura Y, Gose T, Tamai I. PubMed
J Pharm Sci. 2017;106:2491-2498. Circadian Clock Is Involved in Regulation of Hepatobiliary Transport Mediated by Multidrug Resistance-Associated Protein 2. Oh JH, Lee JH, Han DH, Cho S, Lee YJ. PubMed
J Pharm Sci. 2017;106:2499-2508. Application of Quantitative Targeted Absolute Proteomics to Profile Protein Expression Changes of Hepatic Transporters and Metabolizing Enzymes During Cholic Acid-Promoted Liver Regeneration. Miura T, Tachikawa M, Ohtsuka H, Fukase K, Nakayama S, Sakata N, Motoi F, Naitoh T, Katayose Y, Uchida Y, Ohtsuki S, Terasaki T, Unno M. PubMed
J Pharm Sci. 2017;106:2509-2514. Metabolic Activation of Cholestatic Drug-Induced Bile Acid-Dependent Toxicity in Human Sandwich-Cultured Hepatocytes. Ogimura E, Tokizono M, Sekine S, Nakagawa T, Bando K, Ito K. PubMed
J Pharm Sci. 2017;106:2515-2523. Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. Wang C, Huo X, Wang C, Meng Q, Liu Z, Sun P, Cang J, Sun H, Liu K. PubMed
J Pharm Sci. 2017;106:2535-2541. Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine. Mathialagan S, Rodrigues AD, Feng B. PubMed
J Pharm Sci. 2017;106:2542-2550. Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide. Miyake T, Mizuno T, Mochizuki T, Kimura M, Matsuki S, Irie S, Ieiri I, Maeda K, Kusuhara H. PubMed
J Pharm Sci. 2017;106:2558-2565. Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. Takano H, Ito S, Zhang X, Ito H, Zhang MR, Suzuki H, Maeda K, Kusuhara H, Suhara T, Sugiyama Y. PubMed
J Pharm Sci. 2017;106:2566-2575. Investigation of the Importance of Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) in the Active Efflux of Anionic Drugs Across the Blood-Brain Barrier. Kanamitsu K, Kusuhara H, Schuetz JD, Takeuchi K, Sugiyama Y. PubMed
J Pharm Sci. 2017;106:2657-2663. The Organic Anion-Transporting Peptide 2B1 Is Localized in the Basolateral Membrane of the Human Jejunum and Caco-2 Monolayers.Keiser M, Kaltheuner L, Wildberg C, Müller J, Grube M, Partecke LI, Heidecke CD, Oswald S. PubMed
J Pharm Sci. 2017;106:2671-2677. Quantitative Analysis of the Transporter-Mediated Drug-Drug Interaction Between Atorvastatin and Rifampicin Using a Stable Isotope-IV Method. Yamashita S, Hasegawa T, Tachihara M, Minami K, Higashino H, Togashi K, Mutaguchi K, Kataoka M. PubMed
J Pharm Sci. 2017;106:2678-2687. Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different In Vitro-In Vivo Extrapolation Approaches. Izumi S, Nozaki Y, Komori T, Takenaka O, Maeda K, Kusuhara H, Sugiyama Y. PubMed
J Pharm Sci. 2017;106:2688-2694. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. Kashihara Y, Ieiri I, Yoshikado T, Maeda K, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Izumi N, Kusuhara H, Sugiyama Y. PubMed
J Pharm Sci. 2017;106:2704-2714. Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism. Fukuchi Y, Toshimoto K, Mori T, Kakimoto K, Tobe Y, Sawada T, Asaumi R, Iwata T, Hashimoto Y, Nunoya KI, Imawaka H, Miyauchi S, Sugiyam Y. PubMed
J Pharm Sci. 2017;106:2715-2726. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data. Kim SJ, Toshimoto K, Yao Y, Yoshikado T, Sugiyama Y. PubMed
J Pharm Sci. 2017;106:2727-2738. Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologically Based Pharmacokinetic Modeling. Toshimoto K, Tomoda Y, Chiba K, Sugiyama Y. PubMed
J Pharm Sci. 2017;106:2739-2750. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models. Yoshikado T, Maeda K, Kusuhara H, Furihata KI, Sugiyama Y. PubMed
J Pharm Sci. 2017;106:2751-2757. Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L, Benet LZ. PubMed
J Pharm Sci. 2017;106:2780-2786. A Prediction Method for P-glycoprotein-Mediated Drug-Drug Interactions at the Human Blood-Brain Barrier From Blood Concentration-Time Profiles, Validated With PET Data. Matsuda A, Karch R, Bauer M, Traxl A, Zeitlinger M, Langer O. PubMed
J Pharm Sci. 2017;106:2795-2804. Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and In Vitro-In Vivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs. Kimoto E, Bi YA, Kosa RE, Tremaine LM, Varma MVS. PubMed
J Pharm Sci. 2017;106:2805-2814. Current In Vitro Methods to Determine Hepatic Kpuu: A Comparison of Their Usefulness and Limitations. Riede J, Camenisch G, Huwyler J, Poller B. PubMed
J Pharm Sci. 2017;106:2815-2825. Understanding the Interplay Between Uptake and Efflux Transporters Within In Vitro Systems in Defining Hepatocellular Drug Concentrations. Cantrill C, Houston JB. PubMed
J Pharm Sci. 2017;106:2826-2838. The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model. Musther H, Harwood MD, Yang J, Turner DB, Rostami-Hodjegan A, Jamei M. PubMed
Notes
J Pharm Sci. 2017;106:2895-2898. Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. Noguchi S, Nishimura T, Mukaida S, Benet LZ, Nakashima E, Tomi M. PubMed
J Pharm Sci. 2017;106:2899-2903. Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2. Arakawa H, Omote S, Tamai I. PubMed